Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Spesolimab for generalized pustular psoriasis: a prospective study with a 6-month follow-up.

Clinical and experimental dermatology - 17 Aug 2026

Bahloul Emna, Turki Kmar, Nouri Mariem, Sellami Khadija, Hammami Houda, Chaabouni Rim, Boudaya Sonia, Tabka Mariem, Marrakchi Slaheddine, Bougacha Noura, Mokni Mourad, Denguezli Mohamed, Turki Hamida

Abstract excerpt

Generalized pustular psoriasis (GPP) is a rare, life-threatening skin disease. Spesolimab, an anti-interleukin (IL)-36R monoclonal antibody, has shown efficacy in clinical trials, yet real-world data remain limited. We evaluated the real-world effectiveness and safety of spesolimab in patients with GPP and the influence of IL36RN mutation status on treatment response. A prospective study was conducted including...

Topics

Join the communities discussing this publication.

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Follow-Up Studies
Interleukins
Psoriasis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Severity of Illness Index

Treatment Outcome

Source

Identifiers

PMID: 41999186
DOI: 10.1093/ced/llag169

Genes

IL36RN

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Spesolimab for generalized pustular psoriasis: a prospective study with a 6-month follow-up.PMID 41999186Read ↗

Erythema multiforme after initiating spesolimab in a patient with generalized pustular psoriasis with IL36RN mutation.Semantic proximity Read ↗

Clinical advances in biological therapy for generalized pustular psoriasis: a review.Semantic proximity Read ↗

Therapeutic Efficacy of Interleukin 12/Interleukin 23 Blockade in Generalized Pustular Psoriasis Regardless of IL36RN Mutation Status.Semantic proximity Read ↗

Generalized pustular psoriasis: immunological mechanisms, genetics, and emerging therapeutics.Semantic proximity Read ↗

An update on genetic basis of generalized pustular psoriasis (Review).Semantic proximity Read ↗

Successful treatment with interleukin-17A antagonists of generalized pustular psoriasis in patients without IL36RN mutations.Semantic proximity Read ↗

Pathophysiology of generalized pustular psoriasis.Semantic proximity Read ↗

Palmoplantar Pustulosis: Recent Advances in Etiopathogenesis and Emerging Treatments.Semantic proximity Read ↗

Clinical profile of patients with acute generalized pustular psoriasis with and without IL36RN mutations in multi-ethnic Johor Bahru, Malaysia.Semantic proximity Read ↗

microRNA-223 Expression during Flares in Patients with Generalized Pustular Psoriasis Is Regulated by Spesolimab TreatmentSemantic proximity Read ↗

Flare-up of generalized pustular psoriasis following Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine: Two cases without mutations of IL36RN and CARD14 genes.Semantic proximity Read ↗

Novel IL36RN Mutation Identified in Pediatric-Onset Generalized Pustular Psoriasis Causes IL36 Antagonist DegradationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.